Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease.


Journal

PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 28 3 2020
medline: 28 3 2020
entrez: 28 3 2020
Statut: ppublish

Résumé

Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disease, and accounts for a substantial proportion of unplanned hospital admissions. Care bundles for COPD are a set of standardised, evidence-based interventions that may improve outcomes in hospitalised COPD patients. We estimated the cost effectiveness of care bundles for acute exacerbations of COPD using routinely collected observational data. Data were collected from implementation (n = 7) and comparator (n = 7) acute hospitals located in England and Wales. We conducted a difference-in-difference cost-effectiveness analysis using a secondary care (i.e. hospital) perspective to examine the effect on National Health Service (NHS) costs and 90-day mortality of implementing care bundles compared with usual care for patients admitted to hospital with an acute exacerbation of COPD. Adjusted models included as covariates patient age, sex, deprivation, ethnicity and seasonal effects and mixed effects for site. Outcomes and baseline characteristics of up to 12,532 patients were analysed using both complete case and multiply imputed models. Implementation of bundles varied. COPD care bundles were associated with slightly lower secondary care costs, but there was no evidence that they improved outcomes once adjustments were made for site and baseline covariates. Care bundles were unlikely to be cost effective for the NHS with an estimated net monetary benefit per 90-day death avoided from an adjusted multiply imputed model of -£1231 (95% confidence interval - £2428 to - £35) at a high cost-effectiveness threshold of £50,000 per 90-day death avoided. Care bundles for COPD did not appear to be cost effective, although this finding may have been influenced by unmeasured variations in bundle implementation and other potential confounding factors.

Sections du résumé

BACKGROUND BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disease, and accounts for a substantial proportion of unplanned hospital admissions. Care bundles for COPD are a set of standardised, evidence-based interventions that may improve outcomes in hospitalised COPD patients. We estimated the cost effectiveness of care bundles for acute exacerbations of COPD using routinely collected observational data.
METHODS METHODS
Data were collected from implementation (n = 7) and comparator (n = 7) acute hospitals located in England and Wales. We conducted a difference-in-difference cost-effectiveness analysis using a secondary care (i.e. hospital) perspective to examine the effect on National Health Service (NHS) costs and 90-day mortality of implementing care bundles compared with usual care for patients admitted to hospital with an acute exacerbation of COPD. Adjusted models included as covariates patient age, sex, deprivation, ethnicity and seasonal effects and mixed effects for site.
RESULTS RESULTS
Outcomes and baseline characteristics of up to 12,532 patients were analysed using both complete case and multiply imputed models. Implementation of bundles varied. COPD care bundles were associated with slightly lower secondary care costs, but there was no evidence that they improved outcomes once adjustments were made for site and baseline covariates. Care bundles were unlikely to be cost effective for the NHS with an estimated net monetary benefit per 90-day death avoided from an adjusted multiply imputed model of -£1231 (95% confidence interval - £2428 to - £35) at a high cost-effectiveness threshold of £50,000 per 90-day death avoided.
CONCLUSION AND RECOMMENDATIONS CONCLUSIONS
Care bundles for COPD did not appear to be cost effective, although this finding may have been influenced by unmeasured variations in bundle implementation and other potential confounding factors.

Identifiants

pubmed: 32215856
doi: 10.1007/s41669-020-00207-w
pii: 10.1007/s41669-020-00207-w
pmc: PMC7688870
doi:

Types de publication

Journal Article

Langues

eng

Pagination

657-667

Subventions

Organisme : Department of Health
ID : 12/130/53
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P014259/1
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : 12/130/53

Références

BMJ. 2017 Jan 31;356:j557
pubmed: 28148489
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Health Econ. 2013 Apr;22(4):486-500
pubmed: 22447531
BMJ Open Respir Res. 2019 May 30;6(1):e000425
pubmed: 31258918
BMC Pulm Med. 2016 Feb 25;16:35
pubmed: 26916196
Pharmacoeconomics. 2014 Dec;32(12):1157-70
pubmed: 25069632
Health Econ. 2002 Jul;11(5):415-30
pubmed: 12112491
Pharmacoeconomics. 2017 Jan;35(1):43-63
pubmed: 27592021

Auteurs

Padraig Dixon (P)

Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK. Padraig.dixon@bristol.ac.uk.
MRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK. Padraig.dixon@bristol.ac.uk.

William Hollingworth (W)

Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Jonathan Benger (J)

Department of Health and Applied Sciences, University of the West of England, Bristol, BS16 1DD, UK.

James Calvert (J)

North Bristol Trust, Southmead Hospital, Bristol, BS10 5NB, UK.

Melanie Chalder (M)

Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Anna King (A)

Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Stephanie MacNeill (S)

Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Katherine Morton (K)

Department of Health and Applied Sciences, University of the West of England, Bristol, BS16 1DD, UK.

Emily Sanderson (E)

Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Sarah Purdy (S)

Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Classifications MeSH